Luk Vandenberghe, PhD, Director of the Grousbeck Gene Therapy Center at Mass. Eye and Ear and Assistant Professor of Ophthalmology at Harvard Medical School, will receive the American Society of Gene and Cell Therapy (ASGCT) Outstanding New Investigator Award—one of the Society’s highest honors. He will be honored with this award during ASGCT’s 21st Annual Meeting, held in Chicago on May 16-19.
Through the study and development of technologies that overcome current translational hurdles, Dr. Vandenberghe is helping to position gene therapy as a broadly applicable clinical modality in ophthalmology. Previously, he developed a novel adeno-associated viral vector (AAV) platform, and in translational studies, he characterized those for safety and efficacy parameters in large animal models. His current research focuses on gene therapy for neurosensory disorders, especially retinal blindness. In 2011, he co-founded GenSight Biologics, a biotechnology company that pursues innovative ocular gene therapy strategies. Most recently, he co-founded Odylia Therapeutics, a nonprofit corporation dedicated to creating gene therapies for ultra-rare genetic conditions that cause blindness.
ASGCT aims to advance knowledge, awareness, and education in order to lead to the discovery and clinical application of genetic and cellular therapies to alleviate human disease, as well as to bring together scientists, physicians, patient advocates, and other stakeholders to transform the practice of medicine by incorporating the use of genetic and cellular therapies to control and cure human disease.